Skip to content

Prime Medicine

US · PRME #3501 by market cap Listed 2022
3.55 -0.29 -7.55%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:58

Price chart

Pre-market 3.72 -3.13%
After-hours 3.56 +0.28%
Overnight 3.72 -3.13%
5.362.713.552026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on PRME?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +2.9% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 16.1% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days D → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -4,498.1% Better than 1%
Net margin -4,342.4% Better than 1%
Return on equity -146.8% Better than 4%
Return on invested capital -95.2% Better than 2%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 4.7% Better than 83%
6-month return 19.5% Better than 82%
12-month return (ex latest month) 1.1% Better than 35%
Distance below 52-week high 39.9% Better than 28%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.8x Better than 85%
Debt to assets 34.0% Better than 34%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 131.0% Better than 88%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -16.86%
1M -9.44%
3M +9.57%
6M +25.44%
YTD +2.31%
1Y -3.79%
3Y -48.92%

Key statistics

Price & volume

Prev close
3.84
Open
3.70
Day range
3.49 - 3.94
Avg price
3.63
Volume
6.13M
Turnover
22.28M
Amplitude
11.72%
52-week range
2.67 - 5.91

Valuation

P/E
-2.63
P/E (TTM)
-3.66
P/B
93.42
EPS
-1.35
Net profit
-301.04M
Net assets
8.47M

Share structure

Market cap
791.62M
Float cap
536.44M
Shares out
222.99M
Float shares
151.11M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2022-10-20
52-week range 27% of range
2.67 5.91

39.9% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-7.63M net over the window

Short interest

Shares short
29.15M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Prime Medicine (PRME)?

Prime Medicine last traded at 3.55. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Prime Medicine's market cap?

About 791.62M.

What is the P/E ratio of Prime Medicine?

The trailing twelve-month P/E is -3.66. The Valuation tab shows it against the stock's own five-year range.

Does Prime Medicine pay a dividend?

Prime Medicine does not currently pay a regular dividend.

Is Prime Medicine a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 8.20, which implies 131.0% upside from the current price. This is not investment advice.

What is Prime Medicine's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Prime Medicine a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:58:04 · For reference only, not investment advice and not tailored to your situation.

Prime Medicine discussion 0 comments

Add a comment